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RESULTS: Within 2 years of incision, excision and anas-
tomosis of intestine, 14.3% of patients had obstruction,
2.6% required an adhesiolysis for obstruction, and
12.9% underwent additional open colorectal or general
surgery. After other operations of intestine, 17% of pa-
tients had obstruction, 3.1% required an adhesiolysis,
and 20.2% underwent additional surgery. After opera-
tions of rectum, rectosigmoid and perirectal tissue, 15.3%
of patients had obstruction, 5.1% required an adhesioly-
sis, and 16.4% underwent additional surgery.
CONCLUSIONS: In this study of Medicare patients,
bowel obstruction, adhesiolysis for obstruction, and ad-
ditional abdominal surgery occurred more often after ab-
dominal surgery than previously published.
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OBJECTIVE: To compare the effectiveness and costs of
care for nifedipine-CC and amlodipine when used for ini-
tial management of uncomplicated hypertension.
METHODS: A retrospective analysis was conducted us-
ing outpatient pharmacy, provider, and hospital dis-
charge claims records of continuously eligible Pennsylva-
nia Medicaid patients started on either drug in 1994
without prescriptions for other anti-hypertensive agents
or reported cardiovascular complications in the 8 months
prior to initial nifedipine-CC or amlodipine prescription.
Comparison of three indicators of change in prescrip-
tions were evaluated to provide information on medica-
tion effectiveness. Chi-square tests of association were
conducted to evaluate effectiveness indicators while lin-
ear regression was utilized to compare costs.
RESULTS: Patients satisfying inclusion/exclusion crite-
ria who received nifedipine-CC (n  151) or amlodipine
(n  316) had similar demographic characteristics and
levels of comorbidity. A slightly greater percentage of pa-
tients started on nifedipine-CC had prescription records
consistent with cross-over to a different calcium channel
blocker (15.3% versus 10.3%) while a greater percentage
of patients started on amlodipine had records consistent
with cross-over to another class of anti-hypertensive
agent (7.3% versus 13.2%). In adherent patients, other
anti-hypertensive drugs were added to each regimen to a
similar extent and no differences were found in adverse
events that were reported. Total pharmacy costs were de-
termined to be significantly higher (p  0.0001) in pa-
tients started on amlodipine ($2536 higher in patients
with the most comorbidity to $293 in the least).
CONCLUSIONS: The results suggest these drugs have
similar effectiveness and that physicians’ drug preferences
can have important effects on total pharmacy costs.
TPRD4
THE COST-EFFECTIVENESS OF 
IMMUNOSUPPRESSIVE THERAPY AFTER
RENAL TRANSPLANTATION
Clark T, Shih YCT, Dupuis B, Hartzema A
University of North Carolina School of Pharmacy, 
Department of Pharmaceutical Policy and Evaluative Science, 
Chapel Hill, NC, USA
OBJECTIVE: The purpose of this study is to evaluate the
cost-effectiveness of the immunosuppressive regimen, cy-
closporine, mycophenolate mofetil, and prednisone (CMP),
in improving 3-year graft survival in kidney transplant re-
cipients as compared to the immunosuppressive regimen,
cyclosporine, azathioprine, and prednisone (CAP).
METHODS: A sample of kidney transplant recipients re-
ceiving either cadaveric or living donor transplants in
1996 was selected from the United States Renal Data Sys-
tem (USRDS). Direct costs were estimated from Medicare
reimbursements and included: outpatient costs, hospital-
ization costs due to rejection episodes, infectious compli-
cations, or graft failure, dialysis costs due to graft failure,
and medication costs. The effectiveness measure was
length of graft survival and expressed as the total number
of life-months with an intact graft. A Markov model in-
cluding three Markov states (e.g., graft intact, return to
dialysis as a result of graft failure, and death) and two
transient states (e.g., graft rejection and complications)
was used to model the course of progression and continu-
ous risk of graft rejection. The USRDS data were also
used to estimate transplant recipients’ transition proba-
bilities throughout the Markov stages.
RESULTS: Although mycophenolate mofetil costs sub-
stantially more than azathioprine ($6000 versus $1000
annually), preliminary findings suggest that the CMP reg-
imen is more cost-effective than CAP because of the re-
duction in hospitalizations and treatment costs saved by
avoiding acute graft rejection episodes.
CONCLUSIONS: Our study provides valuable informa-
tion regarding the most cost-effective immunosuppressive
regimen to renal transplant centers. Findings from this
study will also be of interest to the Medicare End-Stage
Renal Disease (ERSD) program since a majority of the kid-
ney transplant patients were covered under this program.
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